CIPLA vs PGHL: Stock Comparison

Cipla Ltd vs Procter & Gamble Health Limited

Live data: 22 July 2026, 2:35 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a lower P/E, while Procter & Gamble Health Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 2 of 13 scored metrics and PGHL on 10These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹11,172 Cr
P/E Ratio
CIPLA has a lower P/E
29.83x vs 34.28x
P/B Ratio
CIPLA has a lower P/B
3.36x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹48.01
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.9%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs -2.1%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs -54.6%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLAPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLAPGHL
Live Price₹1,411.5₹6,730.5
Day Change-1.47%-0.72%
Volume12.89 L4,170
52-Week High₹1,673₹6,975
52-Week Low₹1,165.7₹4,707
Distance from 52W High-15.63%-3.51%

Valuation

MetricCIPLAPGHL
Market Cap₹1.14 L Cr₹11,172 Cr
P/E Ratio29.83x34.28x
P/B Ratio3.36x21.36x
EPS₹48.01₹196.64
Book Value₹426.25₹316.01
Dividend Yield0.9%2.34%

Growth

MetricCIPLAPGHL
Revenue Growth (TTM YoY)-2.1%19.1%
EPS Growth (TTM YoY)-54.6%54.6%
Qtr Sales Growth-2.8%19.1%
Qtr Profit Growth-54.6%54.6%

Profitability & Leverage

MetricCIPLAPGHL
ROE11.6%61.6%
ROCE15.5%83.5%
Net Margin13.96%23.22%
Operating Margin20.9%32.4%
Debt to Equity0.02x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLAPGHL
Promoter Holding9.17%0%
FII Holding22.56% 1.37 pp6.33% 0.13 pp
DII Holding31.97% 1.25 pp12.44% 1.23 pp
Public Holding16.25% 0.12 pp29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.